Recursion Pharmaceuticals, Inc. (Recursion) has announced the offering of $200 million of its Class A common stock. The offering is filed under Rule 424(b)(5) with the Securities and Exchange Commission (SEC) and is subject to completion, dated June 26, 2024. The Class A common stock is listed on the Nasdaq Global Select Market under the symbol 'RXRX.' The offering price is assumed to be equal to the last reported sale price of $9.38 per share as of June 25, 2024, which would result in the offering of approximately 21,321,961 shares. The net proceeds from the offering are intended to fund the advancement of Recursion's existing preclinical and clinical programs, platform technologies, foundation model construction, industrialized validation and translation, scientific and technical personnel, as well as for...Show More

Recursion Pharmaceuticals, Inc. (Recursion) has announced the offering of $200 million of its Class A common stock. The offering is filed under Rule 424(b)(5) with the Securities and Exchange Commission (SEC) and is subject to completion, dated June 26, 2024. The Class A common stock is listed on the Nasdaq Global Select Market under the symbol 'RXRX.' The offering price is assumed to be equal to the last reported sale price of $9.38 per share as of June 25, 2024, which would result in the offering of approximately 21,321,961 shares. The net proceeds from the offering are intended to fund the advancement of Recursion's existing preclinical and clinical programs, platform technologies, foundation model construction, industrialized validation and translation, scientific and technical personnel, as well as for general corporate purposes. The underwriters for the offering are Goldman Sachs & Co. LLC, J.P. Morgan, and Allen & Company LLC, with an option to purchase up to an additional $30.0 million of shares. The prospectus supplement, dated June 2024, provides further details on the offering, including risk factors, use of proceeds, and legal matters.